News | October 17, 2006

Boston Scientific to Market Abbott DES Abroad

Boston Scientific has European CE clearance to begin marketing a private-label XIENCE V everolimus-eluting coronary stent made by Abbott Vascular. The stent, named PROMUS, makes BSC the only company offering two distinct DES platforms in the CE geographies.

The company can market PROMUS in the 25 countries of the European Union; the CE mark also supports market registrations in other regulated countries in Asia, Latin America and Eastern Europe.

The addition of PROMUS complements Boston Scientific's TAXUS paclitaxel-eluting stent systems. The company says it expects to launch the PROMUS stent in Europe in 2007.


Related Content

News | Stents Drug Eluting

June 2, 2022 — Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, announced print ...

Home June 02, 2022
Home
News | Stents Drug Eluting

February 16, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced ...

Home February 16, 2022
Home
News | Stents Drug Eluting

January 26, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Boston Scientific's Synergy Megatron Drug ...

Home January 26, 2021
Home
Videos | Stents Drug Eluting

Dean Kereiakes, M.D., medical director, The Christ Hospital Heart and Vascular Center, medical director, The Christ ...

Home October 19, 2020
Home
News | Stents Drug Eluting

October 16, 2020 – Results from the XIENCE 90/28 clinical trials have shown that a shorter course of dual-antiplatelet ...

Home October 16, 2020
Home
News | Stents Drug Eluting

October 11, 2019 — The ultra-thin Supraflex drug-eluting stent (DES) from SMT maintained numerically lower outcomes at ...

Home October 11, 2019
Home
News | Stents Drug Eluting

September 30, 2019 – The first randomized trial to compare a durable polymer drug-eluting stent to a polymer-free drug ...

Home September 30, 2019
Home
News | Stents Drug Eluting

September 30, 2019 — A biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual ...

Home September 30, 2019
Home
News | Stents Drug Eluting

September 5, 2019 — Biotronik's ultrathin Orsiro stent demonstrated superiority over Xience with respect to target ...

Home September 05, 2019
Home
News | Stents Drug Eluting

October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer ...

Home October 01, 2018
Home
Subscribe Now